Food and Drug Administration (FDA) for reducing cardiovascular and kidney disease risk after a major study showed significantly lower rates of heart attack and stroke among people with type 2 diabetes and established atherosclerosis
Toxins (Basel) 2021;13(4):248
The model included the following covariates: age, most recent hemoglobin A1c (if available), overweight/obesity status, body mass index (BMI), hypertension, ischemic heart disease, obstructive sleep apnea, hyperlipidemia, hypercholesterolemia, and prior therapy with antidiabetic agents (including sodium-glucose cotransporter 2 (SGLT2) inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas, metformin, insulins, and other blood glucose-lowering drugs), as shown in Supplementary Table 1
Mar 2011;300(3):F626-627
Isolation of human glucose-6-phosphate dehydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5non-coding region
You might also like Hyssinol $35.99
